Orion Corporation has announced an agreement with Menarini Group to co-market its budesonide/formoterol Easyhaler DPI for the treatment of asthma and COPD in Germany, Italy, Spain, and Portugal. Each company will market the budesonide/formoterol inhaler under its own product name. Orion markets the DPI as Bufoler Easyhaler in the Netherlands, Fobuler in Italy, and Bufomix Easyhaler in other European countries.
Orion will retain marketing rights for the UK, Eastern Europe, and the Nordic countries, while Menarini will distribute the Easyhaler product in France and Turkey. Orion will manufacture the product.
Orion Senior VP of Proprietary Products Markku Huhta-Koivisto commented, “I am excited about the collaboration between Orion and Menarini and look forward to having such a strong partner focusing on respiratory therapy area. The collaboration accelerates the good momentum we have for Easyhaler products in Europe and strengthens Orion`s strategic objective to become a stronger player in the field of respiratory medication.”
Menarini Group General Manager Pio Mei said, “We are most satisfied with the agreement and the co-operation between the Menarini Group and Orion. Menarini`s mission is to make high quality products available to patients all over the world, offering an increasingly wider range of products for the treatment of respiratory diseases.”
Read the Orion press release.
